Saturday 17 October 2026
Export PHIO’s income statement to Excel — free account
Phio Pharmaceuticals Corp.
PHIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 20.0% and free cash flow fell 58.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.06
−6.45%
Follow PHIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(107.58%) | (69.95%) | (76.36%) | (113.71%) | |
| (91.57%) | (63.90%) | (70.87%) | (100.78%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(80.83%) | (43.17%) | (66.41%) | (102.40%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.33) | (1.34) | (0.92) | (1.05) | |
Free Cash Flow |
(7.27) | (7.99) | (10.71) | (12.21) | |
Capital Expenditures |
0.00 | (0.01) | (0.01) | 0.00 | |
| Other line items | |||||
Cash ROIC |
(35.41%) | (19.41%) | (31.99%) | (47.68%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.91 | 0.92 | 0.98 | 0.95 | |
Depreciation/Fixed assets |
0.25 | 0.27 | 0.40 | 0.56 | |
Capex/Depreciation |
(1.33) | (4.00) | (1.75) | (0.80) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.33) | (1.33) | (0.92) | (1.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates